INS and type 1 diabetes mellitus: The value added by clinical translation of stem cell therapy for T1D supersedes previous treatments in the temporal dimension due to its ability to provide functioning beta cells to the patient longitudinally, thus providing for a prolonged period of insulin production during which the patient may not need to rely on other drugs or therapies.